caplacizumab-yhdp (Cablivi)
Jump to navigation
Jump to search
Indications
Dosage
- injection 11 mg
Mechanism of action
- prevents formation of platelet aggregates & microvascular thrombosis by inhibiting von Willebrand factor
- for lasting remission in acquired TTP, may be necessary to restore normal levels of ADAMTS13, (vWF-cleaving protease)
More general terms
References
- ↑ Peyvandi F et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016 Feb 11; 374:511. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26863353
Veyradier A. Von Willebrand Factor - A new target for TTP treatment? N Engl J Med 2016 Feb 11; 374:583. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26863360 - ↑ RxNorm